Overview

Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression

Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.
Phase:
Phase 2
Details
Lead Sponsor:
Zylorion Health
Treatments:
Esketamine
Ketamine